Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Shanghai Kindly Enterprise Development Group Co.,LTD. (603987.SS)
Shanghai, CN
Shanghai Kindly Enterprise Development Group Co.,LTD. (603987.SS) is a global manufacturer and distributor of disposable medical polymer products. The company's core offerings include essential medical devices such as syringes, infusion and transfusion sets, various medical tubes, needles, cannulas, and specialized medical bags. Beyond these primary instruments, they supply a comprehensive range of medical packaging materials, including PPPE composite films, dedicated medical packing films, sterilization indicator strips, Bowie Dick test packs, sterilization indicator tapes, medical wrapping papers, paper bags, and sterilization reels. Their extensive portfolio also features interventional accessories crucial for various procedures, encompassing guide wires, Y-connectors, inflation devices, manifold kits, pressure bandages, angiography syringes, stopcocks, sterile Seldinger needles, introducer sets and accompanying tool kits, pressure transducers, extension tubes, hemostasis balloons, extension lines equipped with needle-free valves, pressure monitoring tubing products, and spine tool kits. Furthermore, they provide a variety of catheters, including guiding, micro, and angiography catheters. Additional products comprise self-sealing pouches, Tyvek® reels, mini-spikes, PE extension tubes, and essential accessories like heparin caps, umbilical cord clamps, and safety boxes. The company also furnishes pre-packaged medical solutions, including suction catheter kits, irrigation kits, and puncture sets. Founded in 1987, Shanghai Kindly Enterprise Development Group Co.,LTD. maintains its headquarters in Shanghai, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.68% | -2.85% | -7.25% | -11.46% | -13.97% | -4.77% | +11.89% | -39.20% | -63.92% | +25.81% | +25.81% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%+1.6% Q1'26: -2.1% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%+14.3% Q1'26: -14.3% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+12.0% ★ Q1'26: -7.9% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+14.1% ★ Q1'26: +11.8% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%+8.8% ★ Q1'26: +6.6% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%-3.0% ★ Q1'26: +0.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×1.15× Q1'26: 2.59× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|---|---|---|
| Revenue |
2.65B
est: 2.81B (-5.9%)
|
3.10B
est: 3.10B (+0.0%)
|
3.12B
est: 3.79B (-17.7%)
|
2.45B
est: 3.39B (-27.6%)
|
2.26B
est: 3.86B (-41.4%)
|
2.30B
est: 4.41B (-47.9%)
|
| EBITDA |
525.07M
est: 561.18M (-6.4%)
|
635.68M
est: 618.27M (+2.8%)
|
565.96M
est: 756.62M (-25.2%)
|
474.00M
est: 676.17M (-29.9%)
|
423.44M
est: 753.66M (-43.8%)
|
481.57M
est: 861.89M (-44.1%)
|
| EBIT |
413.26M
est: 396.22M (+4.3%)
|
510.01M
est: 436.53M (+16.8%)
|
430.48M
est: 534.22M (-19.4%)
|
328.65M
est: 477.41M (-31.2%)
|
275.84M
est: 540.07M (-48.9%)
|
324.65M
est: 617.62M (-47.4%)
|
| Net Income |
202.77M
est: 206.54M (-1.8%)
|
291.40M
est: 276.85M (+5.3%)
|
311.74M
est: 364.74M (-14.5%)
|
230.90M
est: 382.32M (-39.6%)
|
215.33M
est: 439.28M (-51.0%)
|
240.35M
est: 518.18M (-53.6%)
|
| SGA |
465.47M
est: 330.65M (+40.8%)
|
548.03M
est: 364.29M (+50.4%)
|
520.67M
est: 445.81M (+16.8%)
|
391.39M
est: 398.41M (-1.8%)
|
371.10M
est: 556.09M (-33.3%)
|
122.09M
est: 635.95M (-80.8%)
|
| EPS |
0.46
est: 0.47 (-2.1%)
|
0.66
est: 0.63 (+4.8%)
|
0.71
est: 0.83 (-14.5%)
|
0.53
est: 0.87 (-39.1%)
|
0.49
est: 1.03 (-52.4%)
|
0.56
est: 1.22 (-53.9%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-11 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-08 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-07 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-06 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-30 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-29 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-23 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | B- | 2/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Gu Jiajun | Board Secretary | — | female |
| Jian Yong Xiang | Vice Chairman & Deputy GM | — | male |
| Wei Xin Zhang | MD, GM & Director | — | male |
| Xiaoru Shen | Chief Financial Officer, Financial Director & Accounting Supervisor | — | male |
| Yong Zhang | Deputy GM & Director | — | male |
| Zeng Hua Zhang | Deputy GM & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 603987.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
